Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: A meta-analysis

Current Medical Research and Opinion

Volumn 30, Issue 10, 2014, Pages 2033-2039

  Sun, Wei ^a   Hu, Guangyuan ^a   Long, Guoxian ^a   Wang, Junfeng ^a   Liu, Dongbo ^a   Hu, Guoqing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

EGFR inhibitor; Meta analysis; NSCLC; Prediction; Proteomic test

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER PATIENT; COMPUTER PROGRAM; EMBASE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEOMICS; PUBLISHING; SERUM; SERUM BASED PROTEOMIC TEST; WEB OF SCIENCE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925278684     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.934792     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Available at: http://seer.cancer.gov/csr/1975-2010/ [Last accessed 10 November 2013]
3. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
4. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-smallcell lung cancer. J Clin Oncol 2006;24:5034-42
5. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52
6. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74
7. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-20
8. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012;7:1369-81
9. Zhao X, Han RB, Zhao J, et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013;85:119-25
10. Akca H, Demiray A, Yaren A, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet 2013;206:73-80
11. Yeo CD, Kim JW, Kim KH, et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer 2013;81:207-12
12. Ulivi P, Zoli W, Capelli L, et al. Target therapy in NSCLC patients: relevant clinical agents and tumour molecular characterisation. Mol Clin Oncol 2013;1:575-81
13. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
14. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9
15. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-46
16. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010;69:337-40
17. Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer 2012;107:1820-5
18. Spigel DR, Burris HA, Greco FA, et al. Serum proteomic classification in refractory non-small-cell lung cancer treated with erlotinib +/-pazopanib in a randomized placebo-controlled phase II study. Conference: 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Conference Publication. Eur J Cancer 2012;48:147-8
19. Akerley W, Boucher K, Rich N, et al. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer 2013;79:307-11
20. Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2013;79:59-64
21. Stinchcombe TE, Roder J, Peterman AH, et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2013;8:443-51
22. Lazzari C, Novello S, Barni S, et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). Conference: 2013 Annual Meeting of the American Society of Clinical Oncology. Conference Publication. J Clin Oncol 2013;31(18 Suppl 1)
23. Salmon JS, Dang TP, Billheimer D, et al. VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab. Conference: 2008 Annual Meeting of the American Society of Clinical Oncology. Conference Publication. J Clin Oncol 2008;26(15 Suppl):8008
24. Amann JM, Lee J, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer. Conference: 2009 Annual Meeting of the American Society of Clinical Oncology. Conference Publication. J Clin Oncol 2009;27(15 Suppl):8089
25. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of nonsmall cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010;5:169-78
26. Carbone DP, Ding KY, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 trial. J Thorac Oncol 2012;7:1653-60
27. Reckamp KL, Koczywas M, Cristea M, et al. Evaluation of VeriStrat in the randomized, placebo-controlled, phase II trial of erlotinib and high-dose celecoxib in advanced non-small cell lung cancer. Conference: 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. Conference Publication. J Thorac Oncol 2012;7(9 Suppl 4):S337
28. Smit E, Roder H, Grigorieva J, et al. The proteomic classifier VeriStrat® identifies advanced non small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib. Eur J Cancer Supplements 2010;8:193
29. Smit EF, Roder H, Grigorieva J, et al. The proteomic classifier VeriStrat® identifies advanced non small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib. J Thorac Oncol 2011;6:1001
30. rd European Lung Cancer Conference. Conference Publication. J Thorac Oncol 2012;7(6 Suppl 1):S30-1
31. Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 2012;7:40-8
32. Lazzari C, Tiseo M, Gregorc V, et al. Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib. Conference: 2012 Annual Meeting of the American Society of Clinical Oncology. Conference Publication. J Clin Oncol 2012;30(15 Suppl):e18096
33. Spigel D, Burris HA, Greco FA, et al. A randomized phase II study of pazopanib or placebo in combination with erlotinib in patients with advanced non-smallcell lung cancer. Conference: 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. Conference Publication. J Thorac Oncol 2012;7(9 Suppl 4):S208
34. Stinchcombe TE, Roder J, Grigorieva J, et al. A VeriStrat analysis of samples from a randomized phase 2 trial of first-line therapy with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age>=70 years) with stage 3b/4 non-small cell lung cancer. Conference: 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. Conference Publication. J Thorac Oncol 2012;7(9 Suppl 4):S209
35. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S14-23
36. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010;11:851-64
37. Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 2013;80:120-30
38. Indovina P, Marcelli E, Maranta P, et al. Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011;2011:726869
39. Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 2010;19:358-65
40. th International Kidney Cancer Symposium. BJU Int 2012;109(Suppl 5):1-14
41. Akerley WL, Nelson RE, Cowie RH, et al. The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin 2013;29:517-25